We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
Read MoreHide Full Article
Key Takeaways
Rigel Pharmaceuticals expects 2025 sales to rise 60% to $232M, topping prior guidance.
Tavalisse drove $158.9M in 2025 sales, up 52%, while Gavreto and Rezlidhia added momentum.
RIGL guides 2026 product sales of $255-$265M but faces competition from Sanofi and Eli Lilly drugs.
Rigel Pharmaceuticals (RIGL - Free Report) had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse. The two oncology assets, namely Gavreto and Rezlidhia, provide support to RIGL’s top-line momentum.
Based on the unaudited numbers, full-year 2025 product sales are expected to rise 60% year over year to $232 million, exceeding the prior $225-$230 million guidance. This outperformance reflects sustained demand for all marketed drugs.
Tavalisse remained the key driver of revenues for Rigel, generating $158.9 million during the full year, reflecting a 52% year-over-year increase and accounting for more than half of the company’s top line. This drug is approved to treat adults with low platelet counts due to chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Continued strong new patient demand supported the performance, reinforcing the drug’s position as the foundation of Rigel’s commercial portfolio.
The company’s two oncology assets added incremental momentum. The RET-gene targeting drug Gavreto contributed $42.1 million in quarterly sales, while the acute myeloid leukemia (AML) drug Rezlidhia added $31 million. Though smaller in scale compared to Tavalisse, these therapies are gradually expanding and diversifying Rigel’s revenue base.
Rigel projects 2026 net product sales of $255-$265 million, suggesting continued portfolio momentum. The company also expects to achieve positive net income for the full year while continuing to fund existing and new clinical development programs.
Competition in Target Markets
Rigel Pharmaceuticals faces stiff competition from Big Pharma in its target markets.
The company is currently riding on the success of Tavalisse, which faces stiff competition from Sanofi’s (SNY - Free Report) novel BTK inhibitor Wayrilz that was approved for a similar indication in ITP last year. Though both the RIGL and SNY medications are built on different mechanisms, a successful launch of Wayrilz is likely to pose a significant threat to Tavalisse, given the resources available for a large drugmaker like Sanofi.
Gavreto competes in the RET fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancer markets against Eli Lilly’s (LLY - Free Report) Retevmo, another RET inhibitor with an established presence.
RIGL’s Price Performance, Valuation and Estimates
Shares of Rigel Pharmaceuticals have outperformed the industry in the past year, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, RIGL is trading at a slight premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 2.41 times trailing 12-month sales, above the industry average of 2.28 times.
Image Source: Zacks Investment Research
Estimates for Rigel Pharmaceuticals’ 2025 and 2026 EPS have increased during the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
Key Takeaways
Rigel Pharmaceuticals (RIGL - Free Report) had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse. The two oncology assets, namely Gavreto and Rezlidhia, provide support to RIGL’s top-line momentum.
Based on the unaudited numbers, full-year 2025 product sales are expected to rise 60% year over year to $232 million, exceeding the prior $225-$230 million guidance. This outperformance reflects sustained demand for all marketed drugs.
Tavalisse remained the key driver of revenues for Rigel, generating $158.9 million during the full year, reflecting a 52% year-over-year increase and accounting for more than half of the company’s top line. This drug is approved to treat adults with low platelet counts due to chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Continued strong new patient demand supported the performance, reinforcing the drug’s position as the foundation of Rigel’s commercial portfolio.
The company’s two oncology assets added incremental momentum. The RET-gene targeting drug Gavreto contributed $42.1 million in quarterly sales, while the acute myeloid leukemia (AML) drug Rezlidhia added $31 million. Though smaller in scale compared to Tavalisse, these therapies are gradually expanding and diversifying Rigel’s revenue base.
Rigel projects 2026 net product sales of $255-$265 million, suggesting continued portfolio momentum. The company also expects to achieve positive net income for the full year while continuing to fund existing and new clinical development programs.
Competition in Target Markets
Rigel Pharmaceuticals faces stiff competition from Big Pharma in its target markets.
The company is currently riding on the success of Tavalisse, which faces stiff competition from Sanofi’s (SNY - Free Report) novel BTK inhibitor Wayrilz that was approved for a similar indication in ITP last year. Though both the RIGL and SNY medications are built on different mechanisms, a successful launch of Wayrilz is likely to pose a significant threat to Tavalisse, given the resources available for a large drugmaker like Sanofi.
Gavreto competes in the RET fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancer markets against Eli Lilly’s (LLY - Free Report) Retevmo, another RET inhibitor with an established presence.
RIGL’s Price Performance, Valuation and Estimates
Shares of Rigel Pharmaceuticals have outperformed the industry in the past year, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, RIGL is trading at a slight premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 2.41 times trailing 12-month sales, above the industry average of 2.28 times.
Image Source: Zacks Investment Research
Estimates for Rigel Pharmaceuticals’ 2025 and 2026 EPS have increased during the past 30 days.
Image Source: Zacks Investment Research
Rigel Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.